Shopping Cart
- Remove All
- Your shopping cart is currently empty
CTX-2026, a fully human antibody, targets and binds to CD277, demonstrating an anti-tumor effect in ovarian tumor models, and is utilized in cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | CTX-2026, a fully human antibody, targets and binds to CD277, demonstrating an anti-tumor effect in ovarian tumor models, and is utilized in cancer research [1]. |
In vitro | CTX-2026 (1 μg/mL; 12 h) enhances the targeted cytotoxicity of Vγ9Vδ2 T cells from various individuals against BTN3A1-expressing OVCAR3 cells and primary high-grade serous ovarian cancer (HGSOC) cells [1]. |
In vivo | CTX-2026 administered intraperitoneally at a dosage of 5 mg/kg every three days for a duration of 15 days influenced the progression of tumor growth in mice bearing NY-OVCAR3 tumors [1]. |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.